Special Issue "Development of Novel Drugs for Alzheimer's Disease and Myasthenia Gravis"
Deadline for manuscript submissions: closed (21 July 2019).
Prof. Dr. Kamil Kuca
University of Hradec Kralove, Hradec Kralove, Czech Republic
Website | E-Mail
Interests: Antidotes for pesticide and nerve agent poisonings; Alzheimer’s disease treatment; Detergents as disinfectants, nanoparticles; decontamination means; Toxins; Drug design and development; Nanotechnology; IT, parallel computing, ANN; Project management; Scientific management; Technology Transfer; Health economics and Pharmacoeconomics
Searching for novel drugs for the treatment of Alzheimer’s disease (AD) became a main task of current developed societies. There were/are and will be novel drug candidates designed, synthesized and tested throughout many places of the world. Despite tremendous advances in understanding many aspects of AD pathogenesis, there are no proven disease-modifying therapies and the only available ones are minimally effective symptomatic therapies.
Myasthenia gravis (MG) is a neuromuscular disorder that causes weakness in the skeletal muscles. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles. In the case of this disease, efficacy of currently-available drugs is limited.
Both diseases (AD and MG) are associated with an enzyme acetylcholinesterase (AChE), which is a target for development on novel drug candidates for these diseases.
In this Special Issue of International Journal of Molecular Sciences, we would like to discuss all chemico-biological aspects, which are behind the Alzheimer’s disease, as well as Myasthenia gravis.
Prof. Dr. Kamil Kuca
Assoc. Prof. Martin Valis
Dr. Eugenie Nepovimova
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s Disease
- Drug Development
- Computational Chemistry
- Molecular Biology
- In Vitro & In Vivo